| # | Drug | Count |
|---|---|---|
| 0 | GEMCITABINE HYDROCHLORIDE | 588 |
| 1 | PEMBROLIZUMAB | 455 |
| 2 | NIVOLUMAB | 425 |
| 3 | GEMCITABINE | 381 |
| 4 | PACLITAXEL | 343 |
| 5 | TACROLIMUS | 342 |
| 6 | CISPLATIN | 315 |
| 7 | PREDNISOLONE | 268 |
| 8 | PREDNISOLONE ORAL | 268 |
| 9 | PREDNISOLONE ORAL SOLUTION | 268 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PORFIMER SODIUM | 42 | 0.1232 |
| 1 | ADENINE | 2 | 0.0408 |
| 2 | DURVALUMAB | 263 | 0.0122 |
| 3 | CEMIPLIMAB-RWLC | 25 | 0.0120 |
| 4 | LEVOLEUCOVORIN INJECTION | 35 | 0.0114 |
| 5 | GEMCITABINE HYDROCHLORIDE | 588 | 0.0109 |
| 6 | NALDEMEDINE | 18 | 0.0108 |
| 7 | LEVOLEUCOVORIN | 41 | 0.0107 |
| 8 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 37 | 0.0081 |
| 9 | ETHIODIZED OIL | 10 | 0.0077 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1039 |
| 1 | Platinum-based Drug [EPC] | 713 |
| 2 | Corticosteroid [EPC] | 685 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 478 |
| 4 | Kinase Inhibitor [EPC] | 420 |
| 5 | Proton Pump Inhibitor [EPC] | 420 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 409 |
| 7 | Microtubule Inhibitor [EPC] | 374 |
| 8 | Programmed Death Ligand-1 Blocker [EPC] | 274 |
| 9 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 258 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 14 | 0.0203 |
| 1 | Programmed Death Ligand-1 Blocker [EPC] | 274 | 0.0127 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1039 | 0.0105 |
| 3 | Complement C5 Inhibitor [EPC] | 1 | 0.0083 |
| 4 | Bile Acid [EPC] | 158 | 0.0069 |
| 5 | Ileal Bile Acid Transporter Inhibitor [EPC] | 2 | 0.0044 |
| 6 | Interferon gamma Blocker [EPC] | 1 | 0.0042 |
| 7 | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | 9 | 0.0040 |
| 8 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 33 | 0.0038 |
| 9 | CD38-directed Cytolytic Antibody [EPC] | 20 | 0.0034 |